期刊文献+

成本-效果分析在幽门螺杆菌相关性消化性溃疡治疗方案中的应用

下载PDF
导出
摘要 目的探讨不同治疗方案对Hp相关性消化性溃疡治疗的经济效果。方法选取162例Hp阳性的消化性溃疡患者,其中胃溃疡65例,十二指肠球部溃疡97例。随机分成三组:A组54例(奥美拉唑胶囊+阿莫西林胶囊+呋喃唑酮片);B组54例(埃索美拉唑片+阿莫西林胶囊+克拉霉素片);C组54例(枸橼酸铋钾胶囊+阿莫西林胶囊+甲硝唑片)。三组疗程均为4周。观察Hp根除率及溃疡总有效率,并运用药物经济学的成本-效果分析法对Hp相关性消化性溃疡的3种治疗方案进行分析评价。结果Hp根除率A、B、C组分别为92.59%、90.74%、48.15%;溃疡总有效率A、B、C组分别为94.44%、90.74%、40.74%。A、B、c组Hp根除率的成本与效果比分别为14.92、12.74、12.95,溃疡总有效率的成本与效果比分别为14.63、12.74、15.31。A、B、C组Hp根除率的增量成本与效果比分别为17.06、12.50、0,溃疡总有效率的增量成本与效果比分别为14.12、10.65、0,故Hp相关性消化性溃疡患者采用B组治疗方案最佳。结论药物经济学在优化治疗方案、指导合理用药及提高经济效益方面具有重要作用。
出处 《中国医师进修杂志(内科版)》 2008年第2期54-56,共3页 Chinese Journal of Postgraduates of Medicine
  • 相关文献

参考文献5

二级参考文献25

  • 1张万岱,萧树东,胡伏莲,林三仁,胡品津,刘文忠,王继德,徐智民,成虹.对幽门螺杆菌若干问题共识意见[J].世界华人消化杂志,2004,12(10):2457-2458. 被引量:54
  • 2Malfertheinerl P, Megraud F, O′Morain C, et al. The European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection. The Masstricht 2-2000 Consensus Report [J]. Aliment Pharmacol Ther,2002,16 (2):167-180.
  • 3Wang WH, Wong BCY, Mukhopadhyay AK, et al. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong [J]. Aliment Pharmacol Ther, 2000,14(7):901-910.
  • 4Megraud F. Basis for the management of drug-resistant Helicobacter pylori infection [J]. Drugs,2004,64(17): 1 893-1 904.
  • 5Gerrits MM, Van der Wouden EJ, Bax DA, et al. Role of the rdxA and frxA genes in oxygen-dependent metronidazole resistance of Helicobacter pylori [J]. J Med Microbiol,2004,53(Pt 11):1 123-1 128.
  • 6Khan R, Nahar S, Sultana J, et al. T2182C mutation in 23S rRNA is associated with clarithromycin resistance in Helicobacter pylori isolates obtained in Bangladesh [J]. Antimicrob Agents Chemother,2004,48(9):3 567-3 569.
  • 7Gerrits MM, Berning M, Van Vliet AH, et al. Effects of 16S rRNA gene mutations on tetracycline resistance in Helicobacter pylori [J]. Antimicrob Agents Chemother,2003,47(9): 2 984-2 986.
  • 8Kwon DH, Dore MP, Kim JJ, et al. High-level beta-lactam resistance associated with acquired multidrug resistance in Helicobacter pylori [J]. Antimicrob Agents Chemother,2003,47(7): 2 169-2 178.
  • 9Toracchio S, Capodicasa S, Soraja DB, et al. Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin [J]. Dig Liver Dis,2005,37(1):33-38.
  • 10Calvet X, Montserrat A, Guell M, et al. Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study [J]. Eur J Gastroenterol Hepatol,2004, 16(10):987-990.

共引文献204

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部